- Home
- STT vs MRNA Comparison
STT vs MRNA Comparison
Compare STT & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STT | MRNA |
|---|---|---|
| Founded | 1792 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6B | 55.1B |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | STT | MRNA |
|---|---|---|
| Price | $190.09 | $150.85 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 12 |
| Target Price | ★ $148.86 | $34.27 |
| AVG Volume (30 Days) | 1.3M | ★ 27.7M |
| Earning Date | 04-17-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | 14.49 | ★ 21.77 |
| EPS | ★ 6.14 | N/A |
| Revenue | $13,944,000,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $7.66 | $9.36 |
| Revenue Next Year | $3.87 | $15.43 |
| P/E Ratio | $30.58 | ★ N/A |
| Revenue Growth | ★ 7.26 | 4.29 |
| 52 Week Low | $104.64 | $22.28 |
| 52 Week High | $195.93 | $176.66 |
Technical Indicators
Market Signals| Indicator | STT | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 67.71 |
| Support Level | $182.96 | $41.01 |
| Resistance Level | $193.85 | $176.66 |
| Average True Range (ATR) | 4.03 | 15.90 |
| MACD | -0.44 | 3.23 |
| Stochastic Oscillator | 59.79 | 79.98 |
Price Performance
Historical ComparisonAbout STT State Street Corporation
State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $54 trillion in assets under custody and administration, and $5.7 trillion in assets under management, as of Dec. 31, 2025, State Street operates globally in more than 100 geographic markets and employs about 51,500 worldwide.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.